If you only include drop-out numbers directly related to the drug (so exclude unrelated deaths, non-compliance with drug administration etc), it was actually under 10% drop out rate. I recall this may have been elaborated on by the learned contributors here at the time results were released. Great to see that there still using the extended study in recent presentations too.
Ann: Positive topline results from Phase 3 trial in Rett syndrome, page-52
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.90 |
Change
-0.120(0.63%) |
Mkt cap ! $2.427B | |||
| Open | High | Low | Value | Volume |
| $19.20 | $19.28 | $18.55 | $4.750M | 252.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 105 | $18.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.92 | 291 | 9 |
View Market Depth
| Last trade - 12.12pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.05 |
Change
-0.120 ( 0.14 %) |
||||
| Open | High | Low | Volume | ||
| $19.12 | $19.26 | $18.55 | 65501 | ||
| Last updated 12.31pm 05/06/2024 ? | |||||
| NEU (ASX) Chart |